What are the indications for entrectinib? What patients and disease types is it suitable for?

Entrectinib is a targeted drug, a receptor tyrosine kinase inhibitor, mainly used to treat solid tumors carrying NTRK gene fusion mutations. It blocks the signaling of these gene fusion products by targeting and inhibiting three receptor tyrosine kinases: NTRK1, NTRK2, and NTRK3, thereby inhibiting the growth and spread of tumor cells. The indications for entrectinib cover some refractory or metastatic solid tumors, especially those carrying NTRK gene fusion mutations.

Enrectinib is mainly used to treat adult and pediatric patients carrying NTRK gene fusion mutations. Such mutations are commonly found in many different types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, soft tissue sarcoma, liver cancer, pancreatic cancer, etc. NTRKGene fusion is a relatively rare mutation, but it can cause abnormal proliferation of tumor cells and promote the development of cancer. For this type of cancer, entrectinib, as a targeted therapy, can specifically inhibit the growth of tumor cells and has shown good clinical efficacy.

Enrectinib is also suitable for patients who have failed to respond to traditional treatments (such as chemotherapy, immunotherapy, etc.). For these patients, entrectinib provides a new targeted treatment option because other treatments may be ineffective due to genetic characteristics of the cancer (such as NTRK gene fusion). Studies have shown that entrectinib provides longer progression-free survival and is well tolerated in the treatment of these refractory cancers.

Enrectinib has also been approved for use in pediatric patients, particularly those who are young and carry NTRK gene fusion mutations. These pediatric patients often face limited treatment options, and entrectinib, as a targeted drug, can effectively inhibit tumor growth without causing excessive damage to healthy tissue. Clinical data show that entrectinib also has good efficacy and acceptable side effects in pediatric patients, providing an important treatment option.

Reference materials:https://www.roche.com/products/rozlytrek